Tenet Healthcare Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Tenet Healthcare disminuyan en un 8% al año, mientras que se espera que sus ingresos anuales crezcan en un 3.6% al año. Se prevé que el BPA disminuya en un 5.3% por año. Se espera que la rentabilidad financiera sea de 19.7% en 3 años.

Información clave

-35.9%

Tasa de crecimiento de los beneficios

-37.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	17.3%
Tasa de crecimiento de los ingresos	2.7%
Rentabilidad financiera futura	14.5%
Cobertura de analistas	Good
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Tenet Healthcare Corporation's (NYSE:THC) Shareholders Might Be Looking For Exit

Apr 30

Does This Valuation Of Tenet Healthcare Corporation (NYSE:THC) Imply Investors Are Overpaying?

Apr 13

USPI and Providence extend hands to aid ambulatory surgical services

Feb 09

Here's Why Tenet Healthcare (NYSE:THC) Has A Meaningful Debt Burden

Jan 31

Tenet Healthcare: Compressed Multiples Appear Justified

Jan 27

Tenet Health gains on on report David Einhorn's Greenlight has stake

Jan 17

An Intrinsic Calculation For Tenet Healthcare Corporation (NYSE:THC) Suggests It's 22% Undervalued

Jan 13

Tenet Healthcare: Earnings Headwinds With Mixed Technicals

Nov 11

Tenet Healthcare Q3 2022 Earnings Preview

Oct 19

Does Tenet Healthcare (NYSE:THC) Have A Healthy Balance Sheet?

Oct 09

Tenet Healthcare: Mixed Debate, Rate Neutral On Valuation

Aug 25

Tenet Healthcare Q2 2022 Earnings Preview

Jul 20

Previsiones de crecimiento de beneficios e ingresos

NYSE:THC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	22,169	964	N/A	2,358	9
12/31/2025	21,259	891	1,452	2,273	16
12/31/2024	20,327	2,729	2,590	1,800	15
3/31/2024	20,892	2,619	1,755	2,511	N/A
12/31/2023	20,548	611	1,623	2,374	N/A
9/30/2023	20,162	469	1,138	1,971	N/A
6/30/2023	19,897	499	961	1,783	N/A
3/31/2023	19,453	414	462	1,304	N/A
12/31/2022	19,174	410	321	1,083	N/A
9/30/2022	19,040	558	243	1,019	N/A
6/30/2022	19,133	875	414	1,136	N/A
3/31/2022	19,449	957	570	1,262	N/A
12/31/2021	19,485	915	910	1,568	N/A
9/30/2021	19,544	1,079	1,137	1,657	N/A
6/30/2021	19,207	434	1,323	1,818	N/A
3/31/2021	17,901	402	3,333	3,812	N/A
12/31/2020	17,640	399	2,867	3,407	N/A
9/30/2020	17,531	-18	2,929	3,481	N/A
6/30/2020	17,542	-48	2,685	3,307	N/A
3/31/2020	18,454	-112	692	1,352	N/A
12/31/2019	18,479	-226	563	1,233	N/A
9/30/2019	18,292	-228	258	963	N/A
6/30/2019	18,213	-10	197	882	N/A
3/31/2019	18,159	-10	280	946	N/A
12/31/2018	18,313	101	432	1,049	N/A
9/30/2018	18,672	-117	671	1,290	N/A
6/30/2018	18,769	-474	633	1,260	N/A
3/31/2018	19,065	-554	475	1,127	N/A
12/31/2017	19,179	-704	N/A	1,200	N/A
9/30/2017	19,061	-553	N/A	416	N/A
6/30/2017	19,324	-196	N/A	377	N/A
3/31/2017	19,390	-184	N/A	597	N/A
12/31/2016	19,621	-187	N/A	558	N/A
9/30/2016	19,787	-208	N/A	1,042	N/A
6/30/2016	19,630	-227	N/A	1,255	N/A
3/31/2016	19,254	-243	N/A	1,230	N/A
12/31/2015	18,634	-142	N/A	1,026	N/A
9/30/2015	18,073	19	N/A	1,054	N/A
6/30/2015	17,556	57	N/A	793	N/A
3/31/2015	17,101	107	N/A	649	N/A
12/31/2014	16,603	34	N/A	687	N/A
9/30/2014	16,023	-44	N/A	723	N/A
6/30/2014	14,256	-21	N/A	708	N/A
3/31/2014	12,641	-64	N/A	602	N/A
12/31/2013	11,087	-123	N/A	589	N/A
9/30/2013	9,548	-50	N/A	590	N/A
6/30/2013	9,361	-53	N/A	520	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de THC disminuyan en los próximos 3 años (-8% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de THC disminuyan en los próximos 3 años (-8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de THC disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (3.6% al año) de THC crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.6% al año) de THC crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de THC sea baja dentro de 3 años (19.7%).

Tenet Healthcare Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 9.7% to US$123

Tenet Healthcare Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Consensus EPS estimates increase by 144%, revenue downgraded

Price target increased by 17% to US$104

Tenet Healthcare Corporation Provides Consolidated Earnings Guidance for the First Quarter and Full Year of 2024

Price target decreased by 7.4% to US$84.81

Recent updates

EVP, Chief Administrative Officer notifies of intention to sell stock

Price target increased by 9.7% to US$123

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Tenet Healthcare Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Tenet Healthcare Corporation's (NYSE:THC) Shareholders Might Be Looking For Exit

Tenet Healthcare Corporation, Annual General Meeting, May 22, 2024

Tenet Healthcare Corporation, Annual General Meeting, May 22, 2024

Adventist Health System/West completed the acquisition of Sierra Vista Hospital, Inc and Twin Cities Community Hospital, Inc. from Tenet Healthcare Corporation (NYSE:THC).

UCI Medical Center acquired Fountain Valley Regional Hospital, Lakewood Regional Medical Center, Los Alamitos Medical, and Placentia-Linda Hospital from Tenet Healthcare Corporation (NYSE:THC).

Tenet Healthcare Corporation to Report Q1, 2024 Results on Apr 30, 2024

Does Tenet Healthcare (NYSE:THC) Have A Healthy Balance Sheet?

Independent Director recently sold US$1.4m worth of stock

Independent Director notifies of intention to sell stock

Insider recently sold US$1.8m worth of stock

Chairman & CEO exercised options and sold US$2.3m worth of stock

Adventist Health System/West agreed to acquire Sierra Vista Hospital, Inc and Twin Cities Community Hospital, Inc. from Tenet Healthcare Corporation (NYSE:THC) for $550 million.

Independent Director recently sold US$715k worth of stock

New minor risk - Earnings quality

Consensus EPS estimates increase by 144%, revenue downgraded

Price target increased by 17% to US$104

Tenet Healthcare Corporation Provides Consolidated Earnings Guidance for the First Quarter and Full Year of 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Tenet Healthcare: Shrinking To Grow

Novant Health, Inc. completed the acquisition of Coastal Carolina Hospital, East Cooper Medical Center and Hilton Head Hospital and Certain Related Operations in South Carolina from Tenet Healthcare Corporation (NYSE:THC) and Hilton Head Regional Healthcare, L.L.C.

Tenet Healthcare Corporation to Report Q4, 2023 Results on Feb 08, 2024

Tenet Healthcare Corporation (NYSE:THC) Might Not Be As Mispriced As It Looks

Tenet Healthcare Corporation Appoints Vineeta Agarwala to Board of Directors, Member of the Quality, Compliance, and Ethics Committee

Independent Director recently sold US$400k worth of stock

Novant Health, Inc. signed a definitive agreement to acquire Coastal Carolina Hospital, East Cooper Medical Center and Hilton Head Hospital and Certain Related Operations in South Carolina from Tenet Healthcare Corporation (NYSE:THC) for $2.4 billion.

Investor sentiment improves as stock rises 18%

We Think Tenet Healthcare (NYSE:THC) Is Taking Some Risk With Its Debt

Price target decreased by 7.4% to US$84.81

Third quarter 2023 earnings: EPS misses analyst expectations

Tenet Healthcare Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Tenet Healthcare: A Compelling Opportunity Despite Lofty Debt

Tenet Healthcare Corporation to Report Q3, 2023 Results on Oct 30, 2023

Tenet Healthcare Corporation Announces Retirement of Daniel Cancelm as Executive Vice President, Effective December 31, 2023

Tenet Healthcare Corporation Appoints Senator Roy Blunt to Board of Directors

Is Tenet Healthcare (NYSE:THC) Using Too Much Debt?

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Tenet Healthcare Corporation Provides Earnings Guidance for the Third Quarter and Full Year 2023

Tenet Healthcare: Muted Earnings Outlook Doesn't Inspire Confidence For Now

Tenet Healthcare Corporation to Report Q2, 2023 Results on Jul 31, 2023

Insider notifies of intention to sell stock

Tenet Healthcare Corporation Appoints Stephen H. Rusckowski to its Board of Directors

EVP, Chief Administrative Officer recently sold US$1.5m worth of stock

EVP, Chief Administrative Officer notifies of intention to sell stock

Tenet Healthcare Corporation announced that it expects to receive $1.35 billion in funding

Price target increased by 11% to US$82.32

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does This Valuation Of Tenet Healthcare Corporation (NYSE:THC) Imply Investors Are Overpaying?

EVP, Chief Administrative Officer recently sold US$96k worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 7.6% to US$71.65

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Tenet Healthcare Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2023

USPI and Providence extend hands to aid ambulatory surgical services

Now 21% undervalued

Here's Why Tenet Healthcare (NYSE:THC) Has A Meaningful Debt Burden

Tenet Healthcare: Compressed Multiples Appear Justified

Tenet Healthcare Corporation Announces Management Changes

Tenet Healthcare Corporation to Report Q4, 2022 Results on Feb 09, 2023

Tenet Health gains on on report David Einhorn's Greenlight has stake

An Intrinsic Calculation For Tenet Healthcare Corporation (NYSE:THC) Suggests It's 22% Undervalued

Now 22% undervalued after recent price drop

Tenet Healthcare: Earnings Headwinds With Mixed Technicals

CFO & Executive VP recently bought US$474k worth of stock

Investor sentiment deteriorated over the past week

Price target decreased to US$73.12